Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OrganoPlate Graft

Financiado

Cerrado

Organ on a Chip technology for in vitro grafting and vascularisation of 3D tissu...

Organ on a Chip technology for in vitro grafting and vascularisation of 3D tissues PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at cruc... ver más

28/02/2022

MIMETAS

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

MIMETAS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-02-28

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

MIMETAS

2.11M€ | Lider

SANIFIT THERAPEUTICS

494.48K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VOLUME-BIO Volumetric light driven bioprinting capturing complex physio... 2M€ Cerrado

uBeat Mimic human complexity in a Beat to revolutionize the drug d... 75K€ Cerrado

DESARROLLO DE UN BIORREACTOR DE CULTIVO CELUL... DESARROLLO DE UN BIORREACTOR DE CULTIVO CELULAR TOTALMENTE A... 900K€ Cerrado

Design2Flow Disposable well plate inserts and perfusion chambers for eas... 150K€ Cerrado

BIRDIE Bioprinting on chip microphysiological models of humanized k... 3M€ Cerrado

IPT-300000-2010-017 MEDAVAN medicamentos avanzados: celulares e ingeníeria tisul... 216K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2019-02-08
Fecha Fin: 2022-02-28

Líder del proyecto

MIMETAS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at crucial points. The sector is aware of the significant complications in their usage, but lacks better alternatives. Highly advanced technology exists for the culture of cell systems, organs, tumors, etc. outside the body (‘in vitro’). However, the existing culture models lack functional blood vessels – a vital structure inside the body (‘in vivo’). There is a great unmet need for better models of human biology, to speed up both basic research on human biology as well as the development of novel, much needed therapeutic solutions. SOLUTION – OrganoPlate Graft involves the development to market readiness of the first high-throughput in vitro culture method for vascularized tissue that is unrivalled by the available in vitro options. An extensive proof of concept (PoC) for this method has been obtained. The new product will be launched within 6-months post-project and, for the first time, allow for the study and manipulation of human tissues with functional human vascularization. COMPANY – Founded in 2013, the Dutch SME MIMETAS was the first party to commercially exploit organ-on-a-chip technology that enables accurately controlled and monitored in vitro cultivation 3D ‘mini-organs’. MIMETAS currently employs > 60 professionals, generates year-on year multi-million revenues, and is projected to be profitable as of 2020. RESULTS – The results of the 2-year OrganoPlate Graft project will empower Users by aiding them to grow tissues with human vascularization in vitro – enabling the replacement of a wealth of animal experiments and the design of completely novel experiments in research, development and clinical settings. OrganoPlate Graft will cost €3M, employ 10 new FTEs, and is projected to add 40 FTE and >€50M annual revenues to MIMETAS by 2022.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores